The costs of late detection of developmental dysplasia of the hip by unknown
ORIGINAL CLINICAL ARTICLE
The costs of late detection of developmental dysplasia of the hip
Timothy Woodacre • A. Dhadwal • T. Ball •
C. Edwards • P. J. A. Cox
Received: 13 April 2014 / Accepted: 9 June 2014 / Published online: 29 June 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Purpose Debate currently exists regarding the economic
viability for screening for developmental dysplasia of the
hip in infants.
Methods A prospective study of infant hip dysplasia over
the period of 1998–2008 (36,960 live births) was per-
formed to determine treatment complexity and associated
costs of disease detection and hospital treatment, related to
the age at presentation and treatment modality. The
involved screening programme utilised universal clinical
screening of all infants and selective ultrasound screening
of at-risk infants.
Results One hundred and seventy-nine infants (4.8/1,000)
presented with hip dysplasia. Thirty-four infants presented
late ([ 3 months of age) and required closed or open
reduction. One hundred and forty-five infants presented at
\3 months of age, 14 of whom failed early Pavlik harness
treatment. A detailed cost analysis revealed: 131 early
presenters with successful management in a Pavlik harness
at a cost of £601/child; 34 late presenters who required
surgery (36 hips, 19 closed/17 open reductions, one revi-
sion procedure) at a cost of £4,352/child; and 14 early
presenters with failed management in a Pavlik harness
requiring more protracted surgery (18 hips, four closed/14
open reductions, seven revision procedures) at a cost of
£7,052/child.
Conclusions Late detection causes increased treatment
complexity and a sevenfold increase in the short-term costs
of treatment, compared to early detection and successful
management in a Pavlik harness.
Discussion Improved strategies are needed for the 10 %
of early presenting infants who fail Pavlik harness treat-
ment and require the most complex and costly
interventions.
Keywords Developmental hip dysplasia  Screening 
Economics  Ultrasound
Background
We have assessed the cost of both our current screening
and treatment programmes for developmental dysplasia of
the hip (DDH), and have modelled the costs of alternate
screening strategies.
DDH is a common and preventable cause of childhood
disability [1], with a quoted incidence between 1.4/1,000
and 20/1,000 live births [1–3]. Readily identifiable risk
factors exist, including breech position, first birth and a
positive family history [1, 4]. DDH can be detected clini-
cally, including by the combined Ortolani–Barlow
manoeuvre, which has a quoted sensitivity and specificity
of 7–98 and 84–99 %, respectively [5–7]. Ultrasound
scanning (USS) is the gold standard for detecting DDH in
the neonate, with a sensitivity of 100 %, although it can
over-diagnose the condition (labelling natural hip imma-
turity as dysplasia) [8, 9]. Unrecognised or mistreated DDH
can result in long-term hip deformity and morbidity [10].
Early diagnosis whilst the hip and acetabulum are maturing
increases the chance of successful nonoperative manage-
ment in abduction devices, such as the Pavlik harness. Late
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diagnosis, commonly accepted as [ 3 months, increases
the likelihood of surgical intervention being required [1,
10]. DDH is therefore an ideal condition to screen for.
Screening programmes
Screening programmes for DDH have existed since the
1930s. Different programs include the pure clinical
examination of neonates, selective USS of at-risk neonates
and universal neonatal USS. Due to the lower sensitivity
and reliance on clinician skill, screening programs based
purely on clinical examination have a lower rate of early
identification of DDH, resulting in an increased incidence
of late presentation and surgical management. USS
screening incurs more time and cost than pure clinical
screening; however, its supporters maintain that the addi-
tional cost is offset by the reduced incidence of late pre-
senters and interventional treatment [11, 12]. Recent
arguments have been made to abandon screening alto-
gether, due to the time and cost incurred by any DDH
screening program relative to the number of favourable
outcomes achieved. However, an analysis by Sewell and
Eastwood [13] highlighted that this would significantly
increase the rates of late detection, the rates of avascular
necrosis (AVN) secondary to open surgical reduction, and
the requirement for femoral and acetabular osteotomy.
Cost analysis
Limited detailed data exists to provide economic support for
or against DDH screening and the different screening pro-
grams available. The multicentre UK Hip Trial reviewed 629
patients and suggested a decrease in cost of £100 per patient
when USS was used in screening, yet failed to demonstrate
statistical significance [14]. Thaler et al. [11] promoted
universal USS screening by demonstrating a significant
reduction in cost of all surgical and non-surgical treatments
for DDH secondary to its introduction in Tyrol Austria,
accompanied by an increase in annual screening cost of Euro
£57,000. The most comprehensive financial review was
performed by Cleg et al. [12]. This assessed 20 years of
experience in Coventry UK, where the cost of screening
reduced from £5,110 to £3,811 per 1,000 live births fol-
lowing the implementation of universal USS screening. The
number of patients requiring surgical intervention, and more
extensive surgery, decreased. There is, however, still no
clear data detailing the exact costs of different screening
programs relative to increased favourable outcomes.
Current UK guidance
The NHS Newborn and Infant Physical Examination
(NIPE) Programme stated in their 2010 guidance that
universal USS screening was not recommended, but that
there should be selective USS screening based upon risk
factor association and universal neonatal clinical exami-
nation [15]. A child with an abnormality elicited by neo-
natal clinical examination should undergo an USS within
4 weeks. A child with a normal neonatal clinical exami-
nation yet with risk factors for DDH should undergo an
USS at 6 weeks.
Current regional DDH screening programme
Our region currently provides universal clinical screening,
and selective USS screening of children with risk factors
for DDH. All neonates undergo a hip examination within
48 h of birth by a trained member of the paediatric team
and at 6 weeks by a trained member of the community
team (general practitioner or health visitor). All neonates
with clinical suspicion of DDH are referred to the regional
dysplasia clinic. All neonates with a breech delivery or
breech presentation subsequent to 36 weeks gestation or
with a positive family history of DDH are referred for USS
assessment at 6 weeks age and subsequent referral to the
regional dysplasia clinic if DDH is detected.
The regional dysplasia clinic consists of a consultant
paediatric orthopaedic surgeon, a sonographer and a senior
physiotherapist, all with a specialist interest and relevant
training in DDH. All neonates undergo clinical examina-
tion and USS scanning with Graf assessment of DDH
pathology on static US images and additional dynamic
USS. Pavlik harness management is used for infants with
confirmed DDH who are subsequently followed up at bi-
monthly clinics for USS assessment of hip reduction within
harness, with escalation of treatment to surgical interven-
tion if reduction within a Pavlik harness fails.
Aims
We aimed to perform a comprehensive cost analysis of our
current regional model for DDH screening. The primary
outcome measure was to determine treatment complexity
and associated costs of DDH detection and hospital treat-
ment, related to the age at presentation and treatment
modality. The secondary goal was to model the costs of
alternate screening strategies relative to the number of
additional favourable outcomes.
Methods
The Regional Live Birth Data and the STORK neonatal
database were analysed to gain relevant regional epide-
miological information.
326 J Child Orthop (2014) 8:325–332
123
Analysis of current selective screening programme
The regional screening programme in its current form was
introduced in 1997. All children with confirmed DDH had
relevant information regarding their background, referral
modality and treatment prospectively entered onto a secure
dysplasia database. We analysed the database from 1997 to
2008. This provided an 11-year review of the screening and
treatment of regional infant hip dysplasia.
Inclusion criteria
All children with confirmed DDH referred to the dysplasia
clinic were analysed.
Exclusion criteria
• Children referred from out of region, where part or all
of their screening and previous treatment had been
completed separate from the regional screening
program.
• Children with an associated neuromuscular disorder
thought to contribute towards DDH, due to differences
in age of presentation, detection and treatment
modalities.
Cost analysis of current screening programme
Costs were based on 2008 prices and were determined for:
• Neonatal clinical examination screening (at birth and
6 weeks post-partum)
• USS screening
• Dysplasia clinic assessment and Pavlik harness
management
• Inpatient surgical management
• Outpatient follow-up
Costs included:




Cost analysis was divided into
1. The screening of normal children without hip dysplasia
2. Children presenting early (\ 3 months age), allowing
treatment with a Pavlik harness
3. Children presenting late ([ 3 months age) requiring
surgical intervention.
Modelling the costs of alternate screening strategies
The total cost of screening and treatment of DDH over an
11-year period was broken down into its constituent com-
ponents. Accurately determined costs for each component
were then used to model the costs of alternate screening
strategies:
(a) Current selective USS screening of ‘‘at-risk’’ live
births
(b) Universal USS screening of all live births
(c) USS screening of all female live births plus male
‘‘at-risk’’ live births.
Results
Outcome of current selective screening program
Following use of the current screening programme, ana-
lysis of all referrals from 1997 to 2008 demonstrated:
• 36,960 live births screened for risk factors and via
clinical exam.
• 280 children were referred to the regional dysplasia
clinic with confirmed DDH. There were 101 exclusions,
generating 179 appropriate for study.
• The 179 children demonstrated 242 dysplastic hips. The
nature of hip pathology observed is characterised in
Table 1.
• 81 % (n = 145) were successfully identified by the
screening programme and presented early (before
3 months of age).
Table 1 Characterisation of hip
pathology for treatment groups
a 28 hips had radiographic


























131 54 77 17 (1–90) 38 131 16 –
Pavlik fail 14 7 7 26 (1–90) 0 4 17 –
Late
presentation
34 2 32 486 (82–1,955) 2 0 6 28
Totals 179 63 116 – 40 135 39 28
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• 19 % (n = 34) were not identified and presented late
secondary to clinical concern in the community (limited
hip abduction, limb length discrepancy or gait
abnormality).
• The 145 children presenting early demonstrated 168
dislocated (Graf III or IV) hips and 38 critical range
dysplasia (Graf 2c) hips. These were all treated in
Pavlik harnesses. This proved successful for 90 %
(n = 131). Therefore, there was a 90 % success rate for
Pavlik harness management of those children where
DDH was detected early, before 3 months of age,
regardless of Graf classification.
• There was a 10 % failure rate of managing all children
presenting early via a Pavlik harness, requiring
subsequent surgical intervention. This failure of hip
reduction or retention in harness was only observed
with Graf IV hips.
• In 34 children who presented late (over 3 months of
age) both neonatal and 6-week hip examinations were
thought to be normal and no additional risk factors were
present. These children had 36 DDH hips, the majority
being confirmed radiographically as either dislocated or
subluxed (subsequently confirmed on arthrography). In
this group, Pavlik harness was only used as the primary
treatment in three patients. In two of these patients,
dysplasia remained, requiring further intervention.
• Therefore, 33/34 of late presenting patients had
attempted closed reduction under general anaesthesia,
and half of these children failed closed reduction and
required open reduction as a minimum. Table 2 spec-
ifies the type of primary surgical intervention required
for the 10 % of early-presenting patients failing Pavlik
harness management, and for those patients presenting
late. Table 3 specifies the type of secondary surgery
required in addition to the primary intervention.
Cost analysis
Personnel costs per regional DDH clinic and per patient are
summarised in Table 4. The average regional DDH clinic
incurred a cost of £538, with cost per patient being £122 per
new referral and £83 per follow-up. A breakdown of costs for
community surveillance, outpatient treatment and inpatient
treatment are summarised in Tables 5, 6 and 7, respectively.
Table 2 Characterisation of
primary surgical treatment

















33 63 131 0 0 0 0
Pavlik fail 36 30 14 4 16 0 0
Late
presentation
373 47 3 15 19 4 2
Table 3 Characterisation of secondary surgical treatment required for hips in each group
Group Revision open reduction Hip arthrogram Pelvic osteotomy Femoral osteotomy Calculated additional costa
Pavlik success 0 0 0 0 0
Pavlik fail 2 3 5 1 £21,733
Late presentation 0 0 1 1 £5,283
a Additional cost = surgical treatment cost plus cost additional outpatient follow up and extra investigations
Table 4 Breakdown of personnel cost per regional DDH clinic and
per patient










Consultant 10 years 208.53 46.34 34.76
Nurse Band 5 48.15 16.05 8.02
Ultrasonographer Band 7 75.47 25.16 12.58
Physiotherapist Band 6 52.83 8.81 8.81
Administration Band 3 30.78 2.56 2.56
Secretary Band 4 32.74 2.73 2.73
Overheads 89.70 20.33 13.99
Total cost 538.20 121.97 83.35
Table 5 A breakdown of costs for surveillance of DDH in the
community
Surveillance activity Cost per patient £
Data collection 2.60
Normal neonatal hip exam 7.32
Abnormal neonatal hip exam 14.73
GP/health visitor hip exam 5.47
Hip ultrasound 56.00
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Cost analysis of current selective screening program
A breakdown of the cost of the selective regional screening
programme per component parts is demonstrated in
Table 8. The 11-year screening programme cost approxi-
mately £1.14 million, £104,000 per annum. Approximately
25 % (£243,000) of this was accounted for by the neonatal
exam in the community, 20 % (£201,000) by general
practitioner (GP) and health visitor checks in the commu-
nity, 25 % (£244,000) by USS screening, 5 % (£71,000)
by Pavlik harness management and 25 % (£238,000) by
surgical intervention. Of the annual cost of screening, 73 %
(£76,000) was spent demonstrating that 99.5 %
(n = 3,344) had normal hips, and 27 % (£28,000) was
spent demonstrating that the remaining 0.5 % (n = 16)
were dysplastic.
95 % (£21,000) of the annual cost incurred by USS
screening was spent proving that referred infants had nor-
mal hips. Only 5 % (£1,180) of the cost incurred by USS
screening was spent on infants with DDH.
Table 9 demonstrates the cost per child of treatment.
Interestingly, whilst the cost of successfully treating early
presenters via Pavlik harness was £601 and the cost of
treating late presenters was approximately seven times
higher (due to increased cost of interventional treatment),
the cost of failing to successfully manage early presenters
in a Pavlik harness and the subsequent treatment required
was approximately 12 times higher. This additional cost
was due to the increased time and resources spent
attempting to manage within a harness, in addition to the
subsequent, more interventional treatment. Table 10
summarises the previous findings and demonstrates the
cost per treatment modality, per patient, per presentation
per year.
Table 6 A breakdown of costs for outpatient treatment
Outpatient Activity Unit cost £
Pavlik harness 35.00
First regional DDH clinic/harness clinic 121.97
Follow-up regional DDH clinic/harness clinic 83.35
Aftercare physiotherapy 9.36
Consultant follow up outpatient clinic 64.97
Table 7 A breakdown of costs for inpatient treatment
Inpatient activity Unit cost £
Pre-assessment visit 54.85
Inpatient stay: 1 day (for closed hip reduction) 294.07
Inpatient stay: 4 days (for open reduction/osteotomy) 1,167.07
Arthrogram 151.83





Table 8 A breakdown of costs
of the selective regional
screening programme
HV Health Visitor
Number Number/annum Index cost Total 11-year cost Annual cost
Clinical based surveillance £54,000
Data collection 36,960 3,360.0 £2.60 £96,096 £8,736
Neonatal exam
Normal 33,191 3,017.4 £7.32 £242,958 £22,087
Abnormal 3,624 329.5 £14.73 £53,382 £4,853
GP HV exam 36,815 3,346.8 £5.47 £201,378 £18,307
Specialist radiological treatment £22,000
Ultrasound
Normal 3,290 299.1 £56.00 £184,240 £16,749
Immature 334 30.4 £140.00 £46,760 £4,251
DDH 145 13.2 £99.48 £12,975 £1,180
Specialist orthopaedic treatment £28,000
DDH clinic
Pavlik success 131 11.9 £492.64 £64,536 £5,867
Pavlik fail 14 1.3 £490.15 £6,862 £624
Surgical treatment
Late presenter 34 3.1 £4,341.71 £147,618 £13,420
Failed Pavlik 14 1.3 £6,428.28 £89,996 £8,181
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The costs of alternate screening strategies
Table 11 highlights the key differences in cost between the
current screening programme, one that would involve USS
screening all girls and at-risk boys, or universal USS
screening. The cost of the community exams (which
includes the neonatal hip exam) understandably would not
change between the programmes as the same number of
examinations would be performed. The cost incurred by
USS would increase relative to the additional number of
neonates scanned in each program (the additional number
of girls or the total number of neonates, respectively). The
cost incurred by specialist orthopaedic intervention (clinics
and surgery) would increase relative to the number of
neonates identified early, but also failing early
management.
Table 12 highlights the number of additional favourable
outcomes per screening program (the number of neonates
no longer ‘‘missed’’ by the screening program and pre-
senting early rather than late), the additional cost of each
program, and thus the additional cost per favourable
outcome.
Discussion
We have demonstrated the successful application of a
universal clinical and selective USS screening programme
Table 9 Cost per child of screening and treating children with DDH
relative to mode of presentation
Treatment modality Mode of presentation Cost £
(Normal child) – 22
Pavlik harness Early 601
Surgery Late 4,351
Failed Pavlik harness then surgery Early 7,025













Clinical hip examination, selective USS screening, harness treatment
Data collection 95,631 341 37 88 96,097 8,736
Neonatal hip examination 293,963 1,722 196 284 296,166 26,924
6-week hip examination 201,192 717 77 186 202,172 18,379
USS 231,000 11,482 1,271 384 244,137 22,194
Initial assessment clinics 0 42,746 3,713 2,524 48,982 4,453
Physiotherapy input 0 2,023 244 727 2,995 272
Pavlik harness cost 0 6,681 585 160 7,426 675
Hip radiographs 0 0 572 1,399 1,971 179
Follow-up clinics 0 – 996 – 996 91
Subtotal cost 821,786 65,712 7,704 5,787 900,989 81,908
Cost per patient 22 502 544 164
Surgical treatment
Index primary surgery 0 0 65,632 106,120 171,752 15,614
Secondary surgery 0 0 11,285 2,375 13,660 1,242
Subtotal cost 0 0 76,917 108,495 185,412 16,856
Cost per patient 0 0 5,494 7,750
Clinical follow-up
Clinic appointments 0 10,430 5,050 12,450 27,930 2,539
CT/MRI 0 0 2,384 5,829 8,213 747
Hip radiographs 0 2,576 6,292 15,389 24,258 2,205
Subtotal cost 0 13,006 13,726 33,669 60,401 5,491
Cost per patient 0 99 989 990
Overall cost 821,786 78,718 98,347 147,950 1,146,801 104,255
Unit cost per patient 22 691 7,025 4,351
Index primary surgery: hip arthrogram, closed or open reduction, supplemental femoral and pelvic osteotomies, and plaster (spica) changes.
Includes the costs of inpatient stay, theatre costs, all personnel costs, consumables, overheads, administration and secretarial costs
Secondary surgery: additional surgery to deal with complications and residual sequelae, e.g., re-dislocation, residual dysplasia
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for DDH over an 11-year period. This required inter-trust
coordination over a large geographical area and a skilled
dysplasia clinic team. Successful Pavlik harness manage-
ment of patients presenting early (\ 3 months) was 90 %,
irrespective of initial Graf classification of dysplasia. This
is higher than the majority of the published literature [16–
18], with only Uc¸ar et al. [19] publishing equivocal success
rates for both Graf III and IV hips. A relatively large
proportion of Graf IV hips (33/206) was observed in our
study compared to that expected from other DDH series
[16–18]. All 10 % of children presenting early but failing
Pavlik harness management had Graf IV hips. In these
children, harness treatment was discontinued at an early
stage (to avoid iatrogenic induced Pavlik harness disease).
All infants presenting late required surgical intervention,
which concurs with current literature [4].
Comprehensive cost analysis revealed an annual cost of
£104,000 to screen 3,360 neonates, identifying and treating
early 13 patients, ‘‘missing’’ and treating late three patients.
Late detection of DDH caused increased treatment com-
plexity and a sevenfold increase in the short-term costs of
treatment, compared to early detection and successful
management in a Pavlik harness. However improved
strategies are needed for the 10 % of early presenting
infants who fail Pavlik harness treatment and require the
most complex and costly interventions (twelvefold increase
in cost).
The screening programme analysed adheres to UK
Newborn and Infant Physical Examination Programme
(NIPE) guidelines, providing universal clinical screening
and USS screening of patients with abnormal clinical
findings or defined risk factors (including positive family
history, breech position or structural foot abnormalities).
Female neonates are at sevenfold risk of DDH compared to
males. Increasing USS screening to include all females and
at-risk males would generate a further 2.3 favourable out-
comes a year, at a cost of £25,600 per favourable outcome,
but would still result in one male infant presenting late
every 2 years. Increasing to universal USS screening
would double the cost per favourable outcome to £47,800,
but would theoretically eliminate infants presenting late.
Universal USS screening of 3,360 neonates/year would
cost £12 per patient. This is double the cost ascribed by
Clegg et al. [12]; however, our cost analysis is more
comprehensive than the majority described in the literature,
accounting for key additional costs, specifically adminis-
trative and overhead costs, and importantly the cost of
community GP and health visitor checks.
The study is limited by only analysing the short-term
costs of DDH screening in the initial management and
follow-up (to discharge) of patients. It does not assess the
long-term cost of subtle missed DDH to those patients
identified with increasing frequency in young adult hip
clinics with pathology secondary to mild acetabular dys-
plasia, or how increased USS screening would impact on
this [20].
The study adds to current literature by providing a
detailed analysis of the costs and outcomes of an effective
DDH screening programme that adheres to current UK
NIPE guidelines. It provides the means to assess the impact
of an increased use of USS in screening and to determine
the clinical and economic viability of such screening
programmes.
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